We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Treatment with the radiolabeled somatostatin analog [177 Lu-DOTA 0,Tyr3]octreotate: toxicity, efficacy, and survival.
- Authors
Kwekkeboom, Dik J; de Herder, Wouter W; Kam, Boen L; van Eijck, Casper H; van Essen, Martijn; Kooij, Peter P; Feelders, Richard A; van Aken, Maarten O; Krenning, Eric P
- Abstract
Despite the fact that most gastroenteropancreatic neuroendocrine tumors (GEPNETs) are slow-growing, median overall survival (OS) in patients with liver metastases is 2 to 4 years. In metastatic disease, cytoreductive therapeutic options are limited. A relatively new therapy is peptide receptor radionuclide therapy with the radiolabeled somatostatin analog [(177)Lu-DOTA(0),Tyr(3)]octreotate. Here we report on the toxicity and efficacy of this treatment, performed in over 500 patients.
- Publication
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2008, Vol 26, Issue 13, p2124
- ISSN
1527-7755
- Publication type
Journal Article
- DOI
10.1200/JCO.2007.15.2553